# OnCo record nct03686124 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03686124/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03686124", "NCT03686124" ;
  schema:name "ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors"@en ;
  schema:alternateName "ACTengine"@en ;
  schema:description "A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Immatics US, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03686124/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03686124> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2019-05-14" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/immatics/> .